

Special Issue

Tackling Antimicrobial Resistance in Neonatal Infections

Message from the Guest Editors

With this Special Issue, as part of the scientific community, we aim to foster international research to deepen the role of the main determinants leading to adverse outcomes in newborns with SBI. Improved surveillance programs collecting neonatal AMR data and clinical outcomes are critical to allowing benchmarking and designing properly targeted interventions to decrease mortality. Future studies need to focus on improving mortality outcomes and defining the attributable burden of AMR in this population. High-quality reviews and original studies are both welcome. We are particularly interested in the following topics:

- Epidemiology and impact of AMR in neonatal intensive care;
- Relationship between colonization and infections;
- Correlation between resistance and virulence factors/genes;
- Antimicrobial stewardship programs in neonatal settings;
- Outbreaks of MDR rods in NICU.

Keywords: infant, newborn; intensive care units; neonatal; bacteremia; drug resistance; microbial; virulence factors; mortality; antimicrobial stewardship; outbreaks

Guest Editors

Dr. Laura Folgori

Dr. Iliia Bresesti

Dr. Lucia Barcellini

Deadline for manuscript submissions

closed (31 August 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/100682

Antibiotics

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(General Pharmacology, Toxicology and Pharmaceutics)